Akums Drugs and Pharmaceuticals (Akums) had a strong show in Q3FY26 led by CDMO (~16% YoY) and international (~18% YoY) businesses. Volume for CDMO biz surged ~27.6% YoY, though unfavourable pricing and mix partially offset these gains.